These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
774 related articles for article (PubMed ID: 22366309)
1. Orphan drug development: an economically viable strategy for biopharma R&D. Meekings KN; Williams CS; Arrowsmith JE Drug Discov Today; 2012 Jul; 17(13-14):660-4. PubMed ID: 22366309 [TBL] [Abstract][Full Text] [Related]
2. The evolving drug development landscape: from blockbusters to niche busters in the orphan drug space. Kumar Kakkar A; Dahiya N Drug Dev Res; 2014 Jun; 75(4):231-4. PubMed ID: 24829189 [TBL] [Abstract][Full Text] [Related]
3. Medicines for rare (orphan) diseases: an enquiry and proposal for tax-incentives. John JE Drug Discov Today; 2011 Dec; 16(23-24):999-1000. PubMed ID: 22020052 [No Abstract] [Full Text] [Related]
4. [Orphan drugs: drugs for rare diseases]. Schenk M Dtsch Med Wochenschr; 2010 May; 135(18):p17. PubMed ID: 20455291 [No Abstract] [Full Text] [Related]
5. Raising orphans: how clinical development programs of drugs for rare and common diseases are different. Orfali M; Feldman L; Bhattacharjee V; Harkins P; Kadam S; Lo C; Ravi M; Shringarpure DT; Mardekian J; Cassino C; Coté T Clin Pharmacol Ther; 2012 Aug; 92(2):262-4. PubMed ID: 22739137 [TBL] [Abstract][Full Text] [Related]
6. [Authorization and reimbursement of orphan drugs in an international comparison]. Roll K; Stargardt T; Schreyögg J Gesundheitswesen; 2011 Aug; 73(8-9):504-14. PubMed ID: 20848380 [TBL] [Abstract][Full Text] [Related]
7. A cross-national comparative study of orphan drug policies in the United States, the European Union, and Japan: towards a made-in-China orphan drug policy. Liu BC; He L; He G; He Y J Public Health Policy; 2010 Dec; 31(4):407-20; discussion 420-1. PubMed ID: 21119648 [TBL] [Abstract][Full Text] [Related]
8. Drugs for rare diseases: mixed assessment in Europe. Prescrire Int; 2007 Feb; 16(87):36-42. PubMed ID: 17323539 [TBL] [Abstract][Full Text] [Related]
9. Orphanage at the FDA. Chen E J Cardiovasc Transl Res; 2012 Oct; 5(5):735-6. PubMed ID: 21080134 [No Abstract] [Full Text] [Related]
12. Developing treatments for inborn errors: incentives available to the clinician. Haffner ME Mol Genet Metab; 2004 Apr; 81 Suppl 1():S63-6. PubMed ID: 15050976 [TBL] [Abstract][Full Text] [Related]
13. New drugs carry hefty price tags. Makers of leading-edge orphan products asked to cut prices, take smaller profits. Lee J Mod Healthc; 2013 Oct; 43(40):14. PubMed ID: 24340725 [No Abstract] [Full Text] [Related]
14. Financing drug discovery for orphan diseases. Fagnan DE; Gromatzky AA; Stein RM; Fernandez JM; Lo AW Drug Discov Today; 2014 May; 19(5):533-8. PubMed ID: 24269746 [TBL] [Abstract][Full Text] [Related]
15. The US Orphan Drug Act: rare disease research stimulator or commercial opportunity? Wellman-Labadie O; Zhou Y Health Policy; 2010 May; 95(2-3):216-28. PubMed ID: 20036435 [TBL] [Abstract][Full Text] [Related]
16. Duel over discounts. Pharma, providers at odds over 'orphan drugs'. Daly R Mod Healthc; 2012 Jan; 42(4):30-1. PubMed ID: 22359763 [No Abstract] [Full Text] [Related]
17. [Orphan drugs: availability, reliability and reimbursement]. Kreeftmeijer-Vegter AR; van Veldhuizen CK; de Vries PJ Ned Tijdschr Geneeskd; 2012; 156(17):A4252. PubMed ID: 22531041 [TBL] [Abstract][Full Text] [Related]
18. Ethical imperatives of timely access to orphan drugs: is possible to reconcile economic incentives and patients' health needs? Rodriguez-Monguio R; Spargo T; Seoane-Vazquez E Orphanet J Rare Dis; 2017 Jan; 12(1):1. PubMed ID: 28057032 [TBL] [Abstract][Full Text] [Related]